JPRN-jRCTs031220099招募中2 期
Master protocol trial for rare fractions of hepato-pancreato-biliary cancer and neuroendocrine tumor.
Ikeda Masafumi0 个研究点目标入组 50 人开始时间: 2022年5月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Pathologically confirmed undifferentiated carcinoma of the pancreas;
- •(2) Unresectable disease diagnosed by contrast-enhanced CT (chest, abdomen, and pelvis) and/or MRI (abdomen and pelvis) imaging;
- •*If the patient received adjuvant chemotherapy and the diasese recurred within 6 months after the completion, the patient is excluded from this study.
- •(3) At least 20 years of age;
- •(4) Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- •(5) Measurable disease by RECIST v1.1 criteria;
- •(6) No prior treatment for undifferentiated carcinoma of the pancreas;
- •(7) Adequate hematologic and organ function defined by the following laboratory test results, obtained within 7 days prior to study enrollment:
- •1) Absolute neutrophil count (ANC) >=1,500 /mm3,
- •2) Hemoglobin >= 8.0 g/dL,
- •3) Platelet count >= 10^4/mm3,
- •4) Serum total bilirubin <= 2.0 mg/dL,
- •5) Aspartate transaminase (AST) < 100 U/L without liver metastases (< 150 U/L is acceptable if liver metastases are present),
- •6) Alanine transaminase (ALT) < 100 U/L without liver metastases (< 150 U/L is acceptable if liver metastases are present),
- •7) Serum creatinine (Cr) >= 1.2 mg/dL
- •(8) Signed written informed consent form.
- •(1) Pathologically confirmed acinar cell carcinoma of the pancreas;
- •(2) Unresectable disease diagnosed by contrast-enhanced CT (chest, abdomen, and pelvis) and/or MRI (abdomen and pelvis) imaging;
- •*If the patient received adjuvant chemotherapy and the diasese recurred within 6 months after the completion, the patient is excluded from this study.
- •(3) 20-75 years of age;
- •(4) ECOG performance status of 0-1;
- •(5) Measurable disease by RECIST v1.1 criteria;
- •(6) No prior treatment for acinar cell carcinoma of the pancreas;
- •(7) Peripheral motor or sensory neuropathy <= grade 1;
- •(8) None of UGT1A1 polymorphisms (UGT1A1*6/*6, UGT1A1*28/*28, and UGT1A1*6/*28);
- •(9) Adequate hematologic and organ function defined by the following laboratory test results, obtained within 7 days prior to study enrollment:
- •1) Absolute neutrophil count (ANC) >=1,500 /mm3,
- •2) Hemoglobin >= 8.0 g/dL,
- •3) Platelet count >= 10^4/mm3,
- •4) Serum total bilirubin <= 1.5 mg/dL,
- •5) AST < 100 U/L without liver metastases (< 150 U/L is acceptable if liver metastases are present),
- •6) ALT < 100 U/L without liver metastases (< 150 U/L is acceptable if liver metastases are present),
- •7) Cr >= 1.2 mg/dL
- •(10) Signed written informed consent form.
- •(1) Pathologically confirmed adenocarcinoma;
- •(2) Metastatic or recurrent* pancreatic cancer diagnosed diagnosed by contrast-enhanced CT (chest, abdomen, and pelvis) and/or MRI (abdomen and pelvis) imaging;
- •*If the patient received adjuvant chemotherapy and the diasese recurred within 6 months after the completion, the patient is excluded from this study.
- •(3) Presence of UGT1A1 polymorphisms (UGT1A1*6/*6, UGT1A1*28/*28, and UGT1A1*6/*28);
- •(4) 20-75 years of age;
- •(5) ECOG performance status of 0-1;
- •(6) Measurable disease by RECIST v1.1 criteria;
- •(7) No prior treatment for pancreatic cancer;
- •(8) Peripheral motor or sensory neuropathy <= grade 1;
- •(9) Adequate hematologic and organ function defined by the following laboratory test results, obtained within 7 days prior to study enrollment:
- •1) Absolute neutrophil count (ANC) >=1,500 /mm3,
- •2) Hemoglobin >= 8.0 g/dL,
- •3) Platelet count >= 10 x 10^4/mm3,
- •4) Serum total bilirubin <= 2.0 mg/dL,
- •5) AST < 100 U/L without liver metastases (< 150 U/L is acceptable if liver metastases are present),
排除标准
- •(1)History of malignancy (except for adequately treated carcinoma in situ, non-invasive cancer) within 2 years prior to study entry except if the patient has undergone potentially curative therapy with no evidence of that disease recurrence for 2 years;
- •(2)Evidence of uncontrolled, active infection, requiring anti-infectious treatment, except for viral hepatitis;
- •(3)Known central nervous system metastases (imaging required only if participants are symptomatic);
- •(4)Symptomatic ascites or pleural effusion;
- •(5)Significant lung disease, including interstitial lung disease, pulmonary fibrosis, or severe emphysema;
- •(6)Active watery diarrhea;
- •(7)Pregnant, lactating or females of childbearing age unless using highly effective contraception;
- •(8)Male with partner of child-bearing potential unless using highly effective contraception;
- •(9)Patients with significant psychiatric disorder;
- •(10)History of arterial thromboembolism (e.g., myocardial infarction, unstable angina, and cerebral infarction) within 6 months prior to the initiation of study treatment,
- •(11)Significant comorbidities, such as uncontrolled diabetes mellitus, uncontrolled hypertension, New York Heart Association (NYHA) Class III or greater cardiac disease, chronic kidney disease, or liver dysfunction;
- •(12)Requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medication
- •(13)History of hypersensitivity to the study drugs used in each cohort;
- •(14)Patients whose entry in the study is considered by the investigator to be inappropriate.
研究者
相似试验
已完成
1 期
Clinical trial of a new treatment for the hepatocellular carcinoma patients with liver cirrhosisHepatocellular carcinomaJPRN-UMIN000024496niversity of Tsukuba10
已完成
2 期
Phase II study of weekly fractionated hepatic arterial infusion of Sorafenib and Cisplatin for advanced hepatocellular carcinoma.Hepatocellular carcinomaJPRN-UMIN000008571Kansai Medical University Hirakata Hospital33
已完成
不适用
Clinical trial of hepatic arterial infusion chemotherapy with multidrug resistance-associated protein 3-derived peptide for hepatocellular carcinomaHepatocellular carcinoma (HCC)JPRN-UMIN000005678Department of Gastroenterology, Kanazawa University Hospital12
进行中（未招募）
1 期
A Study of LY2157299 in Patients With Liver CancerCarcinoma, hepatocellularMedDRA version: 20.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864EUCTR2010-022338-10-DEEli Lilly and Company204
已完成
不适用
Comparison Study of Operation and PEIT for Small, Solitary Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT00357422Seoul National University Hospital36